Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Genelux Corporation
Genelux Corporation News
Genelux Corporation Quantitative Score
About Genelux Corporation
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Genelux Corporation Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Genelux Corporation Financials
Table Compare
Compare GNLX metrics with: | |||
|---|---|---|---|
Earnings & Growth | GNLX | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | GNLX | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | GNLX | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | GNLX | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Genelux Corporation Income
Genelux Corporation Balance Sheet
Genelux Corporation Cash Flow
Genelux Corporation Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Neutral |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Genelux Corporation Executives
| Name | Role |
|---|---|
| Thomas Zindrick | Chairman, Chief Executive Officer & President |
| Joseph Cappello | Chief Technical Officer |
| Yong Yu | Senior Vice President of Clinical Development |
| Eric Groen | General Counsel, Corporate Secretary, Chief Compliance Officer & Head of Business Development |
| Matthew Pulisic | Chief Financial Officer and Principal Financial & Accounting Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Thomas Zindrick | Chairman, Chief Executive Officer & President | Male | 1959 | 598.05K |
| Joseph Cappello | Chief Technical Officer | 1957 | 363.05K | |
| Yong Yu | Senior Vice President of Clinical Development | 1971 | 242.62K | |
| Eric Groen | General Counsel, Corporate Secretary, Chief Compliance Officer & Head of Business Development | Male | 1971 | -- |
| Matthew Pulisic | Chief Financial Officer and Principal Financial & Accounting Officer | Male | 1984 | -- |
Genelux Corporation Insider Trades
| Date | 2 Jan |
| Name | Litten Jason |
| Role | Chief Medical Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 275000 |
| Date | 2 Jan |
| Name | Litten Jason |
| Role | Officer |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | 17 Nov |
| Name | Yu Yong |
| Role | SVP, Clinical Development |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 973 |
| Date | 21 Aug |
| Name | Yu Yong |
| Role | SVP, Clinical Development |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 3219 |
| Date | 21 Aug |
| Name | Zindrick Thomas |
| Role | President and CEO |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 12673 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 2 Jan | Litten Jason | Chief Medical Officer | Acquired | A-Award | 275000 |
| 2 Jan | Litten Jason | Officer | Disposed | 0 | |
| 17 Nov | Yu Yong | SVP, Clinical Development | Disposed | S-Sale | 973 |
| 21 Aug | Yu Yong | SVP, Clinical Development | Disposed | S-Sale | 3219 |
| 21 Aug | Zindrick Thomas | President and CEO | Disposed | S-Sale | 12673 |